洪都拉斯HIV治疗前与获得性耐药高水平:2016-17年全国代表性调查
治疗前任何耐药患病率26.9%,NNRTI耐药25.9%;病毒载量≥1000 copies/mL者中ADR12和ADR48耐药率分别达86.1%和92.0%,提示需考虑非NNRTI一线方案。
要点
- 治疗前NNRTI耐药高达25.9%,应评估非NNRTI一线方案。
- 治疗12±3个月病毒学失败者中86.1%存在获得性耐药。
- 需加强HIV耐药监测与服药依从性支持。
核心结论
- 洪都拉斯治疗前NNRTI耐药患病率高,需考虑非NNRTI为基础的一线ART方案。
- 获得性耐药在病毒学失败者中极为常见,应加强耐药监测和依从性支持。
研究设计与样本
- 共纳入729名PLHIV,评估治疗前、ADR12和ADR48的HIV耐药。
- 使用Sanger测序分析蛋白酶和逆转录酶序列,以Stanford HIVdb工具判读耐药。
主要发现
- 26.3%(95%CI 20.1%-33.5%)的ART初治者报告既往暴露于抗逆转录病毒药物。
- 治疗前任何耐药患病率为26.9%(95%CI 20.2%-34.9%),NNRTI耐药为25.9%(95%CI 19.2%-33.9%)。
- 有既往抗逆转录病毒暴露的ART初治者NNRTI治疗前耐药更高(P=0.001)。
- ADR12病毒载量抑制率为89.7%(95%CI 85.1%-93.0%),ADR48为67.9%(95%CI 61.7%-73.6%)。
- VL≥1000 copies/mL者中,ADR12任何药物耐药为86.1%(95%CI 48.9%-97.6%),ADR48为92.0%(95%CI 86.8%-95.3%)。
关键数值与推荐
- 治疗前任何耐药:26.9%(95%CI 20.2%-34.9%);NNRTI耐药:25.9%(95%CI 19.2%-33.9%)。
- ADR12中对任何药物耐药:86.1%(95%CI 48.9%-97.6%);对NNRTI和NRTI均耐药:67.1%(95%CI 37.4%-87.5%);对PI耐药:3.8%(95%CI 0.5%-25.2%)。
- ADR48中对任何药物耐药:92.0%(95%CI 86.8%-95.3%);对NNRTI和NRTI均耐药:78.1%(95%CI 66.6%-86.5%);对PI耐药:7.3%(95%CI 1.8%-25.1%)。
临床怎么用
- 在洪都拉斯启动ART时,应考虑非NNRTI为基础的一线方案。
- 对病毒学失败者应进行耐药检测以指导方案更换。
- 加强HIV耐药监测和依从性支持以改善程序效果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pre-treatment HIV drug resistance (HIVDR) to NNRTIs has consistently increased in low-/middle-income countries during the last decade. OBJECTIVES: To estimate the prevalence of pre-treatment HIVDR and acquired HIVDR among persons living with HIV (PLHIV) on ART for 12 ± 3 months (ADR12) and ≥48 months (ADR48) in Honduras. PATIENTS AND METHODS: A nationwide cross-sectional survey with a two-stage cluster sampling was conducted from October 2016 to November 2017. Twenty-two of 54 total ART clinics representing >90% of the national cohort of adults on ART were included. HIVDR was assessed for protease and reverse transcriptase Sanger sequences using the Stanford HIVdb tool. RESULTS: A total of 729 PLHIV were enrolled; 26.3% (95% CI 20.1%-33.5%) ART initiators reported prior exposure to antiretrovirals. Pre-treatment HIVDR prevalence was 26.9% (95% CI 20.2%-34.9%) to any antiretroviral and 25.9% (19.2%-33.9%) to NNRTIs. NNRTI pre-treatment HIVDR was higher in ART initiators with prior exposure to antiretrovirals (P = 0.001). Viral load (VL) suppression rate was 89.7% (85.1%-93.0%) in ADR12 and 67.9% (61.7%-73.6%) in ADR48. ADR12 to any drug among PLHIV with VL ≥1000 copies/mL was 86.1% (48.9%-97.6%); 67.1% (37.4%-87.5%) had HIVDR to both NNRTIs and NRTIs, and 3.8% (0.5%-25.2%) to PIs. ADR48 was 92.0% (86.8%-95.3%) to any drug; 78.1% (66.6%-86.5%) to both NNRTIs and NRTIs, and 7.3% (1.8%-25.1%) to PIs. CONCLUSIONS: The high prevalence of NNRTI pre-treatment HIVDR observed in Honduras warrants consideration of non-NNRTI-based first-line regimens for ART initiation. Programmatic improvements in HIVDR monitoring and adherence support may also be considered.
引用
- Girón-Callejas A, García-Morales C, Mendizabal-Burastero R, et al. High level of pre-treatment and acquired HIV drug resistance in Honduras: a nationally representative survey, 2016-17. J Antimicrob Chemother. 2020. PMID: 32303063. doi:10.1093/jac/dkaa100
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。